iiinova — where your digital self keeps evolving

JCO Journals @jco-asco.bsky.social · 02/10/2026

JCO welcomes Dr. Matthew Davids, Dana-Farber Cancer Institute, as our newest Associate Editor in hematologic malignancies. Welcome @drmdavids.bsky.social!

000

JCO Journals @jco-asco.bsky.social · 30/09/2026

Getting ready for #SABCS26? Consider simultaneous publication with #JCO Journals. Send an inquiry before October 8 for consideration.📅 Learn more at: bit.ly/4hji6tz

000

JCO Journals @jco-asco.bsky.social · 30/09/2026

Can early #ctDNA kinetics tell us more than PSA alone in #mCRPC? This review examines ctDNA across ARPIs, chemotherapy, PARP inhibitors & PSMA-targeted radioligand therapy. Read about the findings. bit.ly/4hepzeK #ProstateCancer #LiquidBiopsy

bit.ly

ASCO Publications

000

JCO Journals @jco-asco.bsky.social · 30/09/2026

🎧 Happy #InternationalPodcastDay! Whether you're commuting, rounding, or taking a break, stay at the forefront of oncology with the JCO Journal Podcasts. 📲 Tune in on Apple Podcasts, Spotify, or your favorite platform: ascopubs.org/podcasts

000

JCO Journals @jco-asco.bsky.social · 29/09/2026

Vemurafenib provides clinically meaningful disease control in BRAF-mutant pediatric and young adult glioma. Component-specific imaging may improve response assessment, while the observed early rebound supports close surveillance and careful planning when stopping therapy. bit.ly/4yY8U55

000

JCO Journals @jco-asco.bsky.social · 28/09/2026

JCO Associate Editor Prof. Brigette Ma joined JCO authors and oncology experts for a dedicated JCO session at #CSCO2026, sharing insights on high-impact research, responsible AI, peer review and global oncology publishing. Thank you to CSCO for a great exchange!

000

JCO Journals @jco-asco.bsky.social · 28/09/2026

The MRF-based habitat framework noninvasively decodes ITH, improves preoperative IDH genotyping, and identifies pathophysiologically distinct subregions with prognostic relevance. Read the article. bit.ly/4yhdHOU

bit.ly

ASCO Publications

000

JCO Journals @jco-asco.bsky.social · 24/09/2026

#GI27 abstract submitted? ✅ Consider simultaneous publication with #JCO Journals. Send an inquiry before Nov. 17 for consideration. Learn how at: bit.ly/4hji6tz

000

JCO Journals @jco-asco.bsky.social · 24/09/2026

This #TAPUR Study provides new information on the efficacy of palbociclib in heavily pretreated patients with ovarian cancer with CDKN2A alterations, warranting further study. Read the article. bit.ly/4rkBMSf #gynonc

001

JCO Journals @jco-asco.bsky.social · 23/09/2026

Listen to the latest @ascocancer.bsky.social #JCO Cancer Stories: The Art of Oncology episode "Purple Blossoms” by Dr. Ramesh Gopal who explores treating an aggressive disease in an underserved area. bit.ly/4hcr4c5

bit.ly

ASCO Publications

010

JCO Journals @jco-asco.bsky.social · 23/09/2026

#JCOPO Editor-in-Chief Emeritus Dr James Ford & @ascocancer.bsky.social TAPUR Study Founding PI Dr Richard Schilsky discuss the 10-year anniversary of the Targeted Agent and Profiling Utilization Registry (TAPUR)™ Study & its relationship w/ the journal. Listen to the podcast. bit.ly/4yPsiRQ

bit.ly

ASCO Publications

010

JCO Journals @jco-asco.bsky.social · 22/09/2026

Now out in #JCO! 👇 Association Between Patient-Reported Outcomes and Health Care Resource Utilization: Toward Developing Patient-Centered Value Measures in Cancer Care. Read the article. bit.ly/4hAysiE

000

JCO Journals @jco-asco.bsky.social · 22/09/2026

Risk prediction in oral potentially malignant disorders remains one of the biggest unmet needs in oral oncology. This new review examines today's tools and where the field needs to go next. Read the article. bit.ly/4hADn36

000

JCO Journals @jco-asco.bsky.social · 21/09/2026

Now out in #JCO 👇 Avatrombopag Versus Placebo for Persistent Chemotherapy-Induced Thrombocytopenia in Gastrointestinal Cancers: The Phase II ACT-GI Trial. Read the article. bit.ly/4y2yjdH

bit.ly

ASCO Publications

000

JCO Journals @jco-asco.bsky.social · 17/09/2026

Advance the science of oncology. As a JCO Journals reviewer, you can sharpen your own research skills while protecting the quality of cancer research. Earn CME credits and FASCO™ points. Learn more and become a reviewer today: bit.ly/3VvklTa #PeerReviewWeek

011

JCO Journals @jco-asco.bsky.social · 15/09/2026

Turn your peer review time into career value. Reviewing for JCO Journals lets you earn CME credits and FASCO™ points and add verified experience to your CV. Help safeguard accuracy, rigor, and scientific integrity in oncology: bit.ly/4xV6X9b

000

JCO Journals @jco-asco.bsky.social · 14/09/2026

🆕 #JCOOA New options are needed for recurrent/metastatic salivary gland cancer. In a phase II study, pemetrexed + pembrolizumab showed: 🔹 ORR: 37.5% 🔹 ORR in salivary duct carcinoma: 63.6% 🔹 Median response duration: 15.3 months Read the article: bit.ly/3UYcQnt

ascopubs.org

ASCO Publications

000

JCO Journals @jco-asco.bsky.social · 11/09/2026

Listen to the latest ASCO JCO Cancer Stories: The Art of Oncology episode "Forty” with host @mikkaelsekeres.bsky.social. Frantz Berthaud discusses grief, survival, and mortality in his poem, which honors his sister’s life and battle with cancer. Listen here: bit.ly/4r5d9sD

000

JCO Journals @jco-asco.bsky.social · 10/09/2026

Not all metastatic hormone-sensitive prostate cancers behave the same. New research shows baseline ctDNA tumor fraction before ADT initiation may help identify patients at higher risk for worse outcomes. Read the article. bit.ly/4cucn2r #ProstateCancer #pcsm

000

JCO Journals @jco-asco.bsky.social · 10/09/2026

Could #ctDNA provide an early window into treatment response in #BreastCancer? In a prospective pilot study, ctDNA clearance within 6 weeks was associated with lower postsurgical tumor burden and ctDNA positivity. Read the article. bit.ly/3SBrMau

bit.ly

ASCO Publications

000

JCO Journals @jco-asco.bsky.social · 09/09/2026

Across 162 studies, early on-treatment #ctDNA reductions were associated with improved overall survival across advanced solid tumors and treatments. Findings support ctDNA dynamics as a potential early trial endpoint, but standardization is essential. Read the article. bit.ly/4cXXq8Y

011

JCO Journals @jco-asco.bsky.social · 08/09/2026

Could biomarker selection broaden immunotherapy’s role in pancreatic cancer? A phase II trial evaluates cemiplimab + gemcitabine in metastatic #PDAC with SWI/SNF alterations. @bottalab.bsky.social @shawnabeynaike.bsky.social Read the article. bit.ly/4xS8V9V

011

JCO Journals @jco-asco.bsky.social · 02/09/2026

ASCO is pleased to name Thomas E. Stinchcombe, MD, FASCO from @dukecancer.bsky.social as the new Editor-in-Chief of JCO, beginning January 2027. Dr. Stinchcombe’s expertise will drive innovation, faster publication timelines, and expanded global reach for high-impact cancer research.

032

JCO Journals @jco-asco.bsky.social · 25/08/2026

JCO Precision Oncology would like to welcome our newest Associate Editor Jill M. Kolesar, PharmD, MS, University of Iowa, Iowa City, IA, USA.

000

JCO Journals @jco-asco.bsky.social · 24/08/2026

ASCO experts Dr. Lesnock of @upmc.com and Dr. Scalici of @winshipcancer.emory.edu explain the New ASCO Living Guideline: Systemic Treatment of Ovarian Cancer Recurrence and the data behind the recommendations. Read the full guideline: bit.ly/4c5RdYe

010

JCO Journals @jco-asco.bsky.social · 20/08/2026

Don't let your story go untold! The deadline for JCO’s Art of Oncology Narrative Medicine Contest is coming up on August 27. Early-career docs & fellows, share your unique journey in cancer care today. Details & submission: bit.ly/4eSna6S

000

JCO Journals @jco-asco.bsky.social · 18/08/2026

Can treatment for intermediate-risk #Rhabdomyosarcoma be refined to improve local control while reducing long-term toxicity? Read the article: bit.ly/4q7tOvp

011

JCO Journals @jco-asco.bsky.social · 14/08/2026

Results from the LiBRA study show early ctDNA clearance predicts BRAF therapy success—while rising signals spot resistance weeks before imaging can. Read the full article here: bit.ly/4q0ts9F

011

JCO Journals @jco-asco.bsky.social · 13/08/2026

The CAST-AI phase II trial evaluates a response-adapted strategy combining systemic therapy, metastasis-directed therapy, consolidative surgery, and tdEV/cfDNA biomarkers to guide treatment and surveillance. Read the full article: bit.ly/4yXUmDd

000

JCO Journals @jco-asco.bsky.social · 12/08/2026

A new study shows patients with ALK-positive NSCLC in Brazil face gaps in testing and targeted treatment—particularly in the public sector. Read full article here: bit.ly/45GszJY

000

JCO Journals @jco-asco.bsky.social · 11/08/2026

Phase III ATALANTE/ENGOT-ov29 study: Adding atezolizumab to chemo + bevacizumab did not improve PFS. However, longer follow-up showed an exploratory 5-month OS improvement and higher 5-year survival rates. Read more: bit.ly/4q0qIJp

000

JCO Journals @jco-asco.bsky.social · 10/08/2026

This Editorial by Cohen and Yurgelun was published in #JCOCCI on "Machine Learning Algorithm for the Detection of Tumor Microsatellite Instability Based on Multiomics Biomarkers," by Strickland et al. Co-authored by @mattyurgelun.bsky.social Read the article. bit.ly/4hqz8rj

010

JCO Journals @jco-asco.bsky.social · 10/08/2026

QoL was pre-specified in 85% of 80 phase III GU cancer trials but reported in only 47.5%. Positive trials had nearly 5× greater odds of reporting QoL than negative trials, raising concerns about selective disclosure. Read the full study here: bit.ly/4wFyr1X

000

JCO Journals @jco-asco.bsky.social · 07/08/2026

In this phase II safety analysis of 17 patients, the approach was feasible, but uncommon serious immune-mediated and hematologic toxicities highlight the need for vigilant monitoring. Read the full article: bit.ly/453PnTX

010

JCO Journals @jco-asco.bsky.social · 06/08/2026

A new Bayesian multistate framework analyzes 12 patient state transitions to identify mechanisms of survival benefit and improves interim prediction accuracy 82% over conventional approaches. Read the full study here: bit.ly/4haDzGG

000

JCO Journals @jco-asco.bsky.social · 29/07/2026

New study by Fukuda et al: Early-phase targeted trials offer meaningful activity for gynecologic cancer patients with no remaining standard options. Response rates improved most with treatment guided by biomarkers. Learn more: bit.ly/4fS1lpJ #gynonc

000

JCO Journals @jco-asco.bsky.social · 28/07/2026

Listen to the latest JCO Art of Oncology episode with host @mikkaelsekeres.bsky.social: "Taking Responsibility” by Dr. Hicks-Courant, who shares how caring for her father with ALS shaped how she approached her work as a gynecologic oncologist. 🎧: bit.ly/3T9Ny5d #gynonc

001

JCO Journals @jco-asco.bsky.social · 27/07/2026

#JCOCCI now accepts Resource Reports—new articles on tools, databases & software for cancer researchers & clinicians. Read the first report by Roy et al. & Dr. Jeremy Warner's editorial: bit.ly/4bv9XAj & bit.ly/4c1UIyK

ascopubs.org

ASCO Publications

000

Reposted by JCO Journals

Fumiko Ladd Chino, MD FASCO @fumikochino.bsky.social · 20/07/2026

Dr Robin Zon's @ascocancer.bsky.social presidential address focused on translating EBM into better outcomes for pts through meaningful investments in tech, advocacy, & community. 🎙️new #JCOOP podcast feat. former ASCO President on leadership & future vision in oncology ascopubs.org/do/roadmap-a...

JCO ONCOLOGY PRACTICE PODCAST
JUL 20, 2026|
Podcast: A RoadMap to Achieve High Quality Care for All: Walking in Beauty and Strength with Past President Dr. Robin Zon
Dr. Fumiko Chino (Host), Dr. Robin Zon (Guest)
Dr. Chino speaks with ASCO President Dr. Robin Zon about leadership in oncology and what it takes to steer a global oncology society in turbulent times.
ASCO
小川
JCO
Oncology Practice
JCO Oncology Practice Podcast
FOLLOW

051

JCO Journals @jco-asco.bsky.social · 20/07/2026

Nearly 30% of young cancer patients are never told treatment can affect fertility. New data reveals major demographic disparities in awareness, highlighting a critical need for equitable fertility counseling in oncology. Read the full patient-centered study here: bit.ly/4fmUbZm

000

JCO Journals @jco-asco.bsky.social · 17/07/2026

A novel oral cancer vaccine (B440) shows promise in a Phase I trial for metastatic urothelial cancer. Key wins: safe, induced WT1-specific T-cell responses, & potential renewed sensitivity to immunotherapy. Read the full breakthrough here: bit.ly/3Rvxt9j

000

JCO Journals @jco-asco.bsky.social · 16/07/2026

New study in JCO OA shows rising diversity among FASCO recipients (2007–2024) after 2022 merit-based reforms, though disparities remain. Vital insights for equitable oncology leadership. Read the full study here: bit.ly/4f83xI2

010

JCO Journals @jco-asco.bsky.social · 14/07/2026

JCO invites trainees and early-career oncologists to share personal, empathetic essays on the human side of cancer care. Reflect on your journey & inspire your peers. Deadline is August 27, 2026. Share your story and submit today: bit.ly/4eSna6S

011

JCO Journals @jco-asco.bsky.social · 10/07/2026

Later-line advanced gastric cancer therapy is tough. This phase II trial of FTD/TPI + ramucirumab showed feasible delivery, a 76.9% DCR, 4.0-mo median TTF, and manageable toxicity (mostly neutropenia). It offers key data on routine-care tolerability. Learn more: bit.ly/3R9iUYV

000

JCO Journals @jco-asco.bsky.social · 09/07/2026

Who gets represented in cancer clinical trials? An analysis across 3 NCI cancer centers found enrollment gaps varied by site for minorities, rural residents, Medicaid patients, & non-English speakers. Measuring this is step 1 to equity. Read the full article: bit.ly/4vcUaNt

000

JCO Journals @jco-asco.bsky.social · 08/07/2026

How do pediatric phase 1 trials shape targeted therapy? By balancing efficacy with long-term safety. A new study on tovorafenib established phase 2 dosing and flagged growth suppression risks for new pediatric low-grade glioma treatments. Read the full article: bit.ly/4eHA7lm

010

JCO Journals @jco-asco.bsky.social · 07/07/2026

Vincristine neuropathy in pediatric ALL can persist past therapy. This UKALL 2011 sub-study used gait analysis to show that omitting maintenance pulses safely reduced this functional burden—a vital reminder for survivorship. Read more: bit.ly/4y4lujG

000

JCO Journals @jco-asco.bsky.social · 06/07/2026

Over 1.3M cervical cancer deaths were avoided across 48 countries since peak mortality. This study highlights the impact of HPV vaccination, screening, and treatment, showing both progress and remaining challenges toward elimination. Read the full article: bit.ly/4wjxWtZ

000

JCO Journals @jco-asco.bsky.social · 03/07/2026

Read on for recommendations on how to maximize research potential of limited biopsy tissue and optimize workflows to improve assay success rates and data reproducibility in large-scale oncology trials. Read the article. bit.ly/3QHly87

000

JCO Journals @jco-asco.bsky.social · 02/07/2026

#JCO welcomes Tom Wei-Wu Chen, MD, PhD, as our newest Consultant Editor. Welcome, Dr. Chen!

000